Invention Application
- Patent Title: Novel Compounds
-
Application No.: US16129867Application Date: 2018-09-13
-
Publication No.: US20190010135A1Publication Date: 2019-01-10
- Inventor: Weichun Chen , Ebere F. Igboko , Xichen Lin , Hongfu Lu , Feng Ren , Paul Bryan Wren , Zhongmiao Xu , Ting Yang , Lindong Zhu
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
- Priority: CNPCT/CN2014/000545 20140529; CNPCT/CN2014/083380 20140731; CNPCT/CN2015/077947 20150430
- Main IPC: C07D307/18
- IPC: C07D307/18 ; C07D241/04 ; C07D309/08 ; C07C317/50 ; C07C317/42 ; C07C311/47 ; C07D305/06 ; C07D213/34 ; C07D295/135 ; C07D211/54 ; C07D207/10 ; C07D487/04 ; C07D471/04 ; C07D239/26 ; C07D233/64
Abstract:
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
Public/Granted literature
- US10336719B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors Public/Granted day:2019-07-02
Information query
